BML 5.06 No Change ▼ 0.00 (0%)
BOP 12.36 Increased By ▲ 0.50 (4.22%)
CNERGY 7.17 Decreased By ▼ -0.02 (-0.28%)
CPHL 86.95 Increased By ▲ 0.07 (0.08%)
DCL 14.81 Decreased By ▼ -0.14 (-0.94%)
DGKC 168.46 Increased By ▲ 0.23 (0.14%)
FCCL 46.15 Decreased By ▼ -0.06 (-0.13%)
FFL 15.97 Decreased By ▼ -0.03 (-0.19%)
GCIL 27.05 Decreased By ▼ -0.08 (-0.29%)
HUBC 141.44 Increased By ▲ 0.44 (0.31%)
KEL 5.12 Increased By ▲ 0.02 (0.39%)
KOSM 6.75 Increased By ▲ 0.10 (1.5%)
LOTCHEM 20.90 Decreased By ▼ -0.26 (-1.23%)
MLCF 84.50 Decreased By ▼ -0.43 (-0.51%)
NBP 119.80 Decreased By ▼ -0.06 (-0.05%)
PAEL 42.37 Increased By ▲ 0.40 (0.95%)
PIAHCLA 22.27 Decreased By ▼ -0.96 (-4.13%)
PIBTL 9.03 Increased By ▲ 0.16 (1.8%)
POWER 14.10 No Change ▼ 0.00 (0%)
PPL 169.60 Decreased By ▼ -1.32 (-0.77%)
PREMA 43.90 Decreased By ▼ -0.17 (-0.39%)
PRL 32.96 Decreased By ▼ -0.08 (-0.24%)
PTC 24.68 Decreased By ▼ -0.22 (-0.88%)
SNGP 119.41 Increased By ▲ 0.07 (0.06%)
SSGC 45.31 Decreased By ▼ -0.22 (-0.48%)
TELE 8.23 Decreased By ▼ -0.07 (-0.84%)
TPLP 10.46 Decreased By ▼ -0.22 (-2.06%)
TREET 24.03 Decreased By ▼ -0.35 (-1.44%)
TRG 58.83 Increased By ▲ 0.97 (1.68%)
WTL 1.55 Decreased By ▼ -0.03 (-1.9%)
BR100 13,511 Increased By 49.6 (0.37%)
BR30 39,479 Decreased By -51.6 (-0.13%)
KSE100 133,127 Increased By 549.9 (0.41%)
KSE30 40,433 Increased By 74.4 (0.18%)

FRANKFURT: BioNTech said on Wednesday it would expand an ongoing clinical trial programme to develop new vaccines and patterns of administration for better protection against the dominant Omicron coronavirus variant.

The addition of cohorts to a trial programme initially unveiled in January comes as global infection numbers are on the rise and protection against infection from its established Comirnaty vaccine, co-developed with Pfizer, has waned.

Thanks to 10.3 billion euros ($11.48 billion) in net income in 2021, the German biotech firm plans to spend between 1.4 billion and 1.5 billion euros on research and development this year.

Pfizer-BioNTech seek US approval of second Covid booster for 65+

It also plans to buy back up to $1.5 billion worth of shares over two years and pay a special dividend of 486 million euro in total, or 2 euros per share.

It reiterated its 2022 vaccine revenue guidance of between 13 billion and 17 billion euros.

Comments

Comments are closed.